| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 6 securities · may seek to influence control | ||||||
|
BiomX Inc.
13D/A
PHGE · 09090D509
|
4.7% |
6/16/2026
Event 6/12/2026
|
||||
| Deerfield Private Design Fund V, L.P. | 2.4% | |||||
| Deerfield Mgmt V, L.P. | 2.4% | |||||
| Deerfield Healthcare Innovations Fund II, L.P. | 2.4% | |||||
| Deerfield Mgmt HIF II, L.P. | 2.4% | |||||
| Deerfield Management Company, L.P. | 4.7% | |||||
| James E. Flynn | 4.7% | |||||
|
Larimar Therapeutics, Inc.
13D/A
LRMR · 517125100
|
34.4% |
3/2/2026
Event 2/27/2026
|
||||
| Deerfield Private Design Fund III, L.P. | 10.3% | |||||
| Deerfield Healthcare Innovations Fund, L.P. | 7.9% | |||||
| Deerfield Private Design Fund IV, L.P. | 10.3% | |||||
| Deerfield Partners, L.P. | 6.0% | |||||
| Deerfield Mgmt III, L.P. | 10.3% | |||||
| Deerfield Mgmt HIF, L.P. | 7.9% | |||||
| Deerfield Mgmt IV, L.P. | 10.3% | |||||
| Deerfield Mgmt, L.P. | 6.0% | |||||
| Deerfield Management Company, L.P. | 34.4% | |||||
| James E. Flynn | 34.4% | |||||
|
ARS Pharmaceuticals, Inc.
13D/A
SPRY · 82835W108
|
7.8% |
8/1/2025
Event 7/30/2025
|
||||
| Deerfield Mgmt III, L.P. | 3.9% | |||||
| Deerfield Private Design Fund III, L.P. | 3.9% | |||||
| Deerfield Mgmt IV, L.P. | 3.9% | |||||
| Deerfield Private Design Fund IV, L.P. | 3.9% | |||||
| Deerfield Management Company, L.P. | 7.8% | |||||
| James E. Flynn | 7.8% | |||||
|
BiomX Inc.
13D/A
PHGE · 09090D103
|
10.0% |
3/3/2025
Event 2/27/2025
|
||||
| Deerfield Private Design Fund V, L.P. | 10.0% | |||||
| Deerfield Mgmt V, L.P. | 10.0% | |||||
| Deerfield Healthcare Innovations Fund II, L.P. | 10.0% | |||||
| Deerfield Mgmt HIF II, L.P. | 10.0% | |||||
| Deerfield Management Company, L.P. | 10.0% | |||||
| James E. Flynn | 10.0% | |||||
|
Singular Genomics Systems, Inc.
13D/A
OMIC · 82933R308
|
100.0% |
2/25/2025
Event 2/21/2025
|
||||
| Deerfield Mgmt IV, L.P. | 100.0% | |||||
| Deerfield Private Design Fund IV, L.P. | 100.0% | |||||
| Deerfield Management Company, L.P. | 100.0% | |||||
| James E. Flynn | 100.0% | |||||
|
Acutus Medical, Inc.
13D/A
AFIB · 005111109
|
9.1% |
1/28/2025
Event 1/27/2025
|
||||
| Deerfield Mgmt III, L.P. | 5.4% | |||||
| Deerfield Private Design Fund III, L.P. | 5.4% | |||||
| Deerfield Mgmt, L.P. | 4.9% | |||||
| Deerfield Partners, L.P. | 4.9% | |||||
| Deerfield Management Company, L.P. | 9.1% | |||||
| James E. Flynn | 9.1% | |||||
| Schedule 13G · 27 securities · passive | ||||||
|
Climb Bio, Inc.
13G
CLYM · 28658R106
|
5.3% |
10/28/2026
Event 10/27/2026
|
||||
| Deerfield Mgmt, L.P. | 5.3% | |||||
| Deerfield Management Company, L.P. | 5.3% | |||||
| Deerfield Partners, L.P. | 5.3% | |||||
| James E. Flynn | 5.3% | |||||
|
Enhabit, Inc.
13G/A
EHAB · 29332G102
|
0% |
8/13/2026
Event 6/30/2026
|
||||
| Deerfield Mgmt, L.P. | 0% | |||||
| Deerfield Management Company, L.P. | 0% | |||||
| Deerfield Partners, L.P. | 0% | |||||
| James E. Flynn | 0% | |||||
|
Cogent Biosciences, Inc.
13G/A
COGT · 19240Q201
|
2.9% |
8/13/2026
Event 6/30/2026
|
||||
| Deerfield Mgmt, L.P. | 2.9% | |||||
| Deerfield Management Company, L.P. | 2.9% | |||||
| Deerfield Partners, L.P. | 2.9% | |||||
| James E. Flynn | 2.9% | |||||
|
Nuvalent, Inc.
13G/A
NUVL · 670703107
|
0% |
7/17/2026
Event 7/15/2026
|
||||
| Deerfield Management Company, L.P. | 0% | |||||
| Deerfield Mgmt IV, L.P. | 0% | |||||
| Deerfield Private Design Fund IV, L.P. | 0% | |||||
| Deerfield Mgmt HIF, L.P. | 0% | |||||
| Deerfield Healthcare Innovations Fund, L.P. | 0% | |||||
| Deerfield Mgmt, L.P. | 0% | |||||
| Deerfield Partners, L.P. | 0% | |||||
| James E. Flynn | 0% | |||||
|
Inspire Medical Systems, Inc.
13G/A
INSP · 457730109
|
4.5% |
5/14/2026
Event 5/14/2026
|
||||
| Deerfield Mgmt, L.P. | 4.5% | |||||
| Deerfield Management Company, L.P. | 4.5% | |||||
| Deerfield Partners, L.P. | 4.5% | |||||
| James E. Flynn | 4.5% | |||||
|
Foghorn Therapeutics Inc.
13G/A
FHTX · 344174107
|
8.6% |
5/14/2026
Event 3/31/2026
|
||||
| Deerfield Mgmt, L.P. | 8.6% | |||||
| Deerfield Management Company, L.P. | 8.6% | |||||
| Deerfield Partners, L.P. | 8.6% | |||||
| James E. Flynn | 8.6% | |||||
|
BioCryst Pharmaceuticals, Inc.
13G/A
BCRX · 09058V103
|
6.8% |
2/12/2026
Event 12/31/2025
|
||||
| Deerfield Mgmt, L.P. | 6.8% | |||||
| Deerfield Management Company, L.P. | 6.8% | |||||
| Deerfield Partners, L.P. | 6.8% | |||||
| James E. Flynn | 6.8% | |||||
|
CalciMedica Inc.
13G/A
CALC · 38942Q202
|
4.3% |
2/6/2026
Event 2/6/2026
|
||||
| Deerfield Mgmt, L.P. | 4.3% | |||||
| Deerfield Management Company, L.P. | 4.3% | |||||
| Deerfield Partners, L.P. | 4.3% | |||||
| James E. Flynn | 4.3% | |||||
|
Certara, Inc.
13G/A
CERT · 15687V109
|
4.9% |
11/25/2025
Event 11/25/2025
|
||||
| Deerfield Mgmt, L.P. | 4.9% | |||||
| Deerfield Management Company, L.P. | 4.9% | |||||
| Deerfield Partners, L.P. | 4.9% | |||||
| James E. Flynn | 4.9% | |||||
|
Cullinan Therapeutics, Inc.
13G/A
CGEM · 230031106
|
4.95% |
11/13/2025
Event 9/30/2025
|
||||
| Deerfield Mgmt, L.P. | 4.95% | |||||
| Deerfield Management Company, L.P. | 4.95% | |||||
| Deerfield Partners, L.P. | 4.95% | |||||
| James E. Flynn | 4.95% | |||||
|
Lomond Therapeutics Holdings, Inc.
13G/A
54173L101
|
8.4% |
11/13/2025
Event 9/30/2025
|
||||
| Deerfield Mgmt, L.P. | 8.4% | |||||
| Deerfield Management Company, L.P. | 8.4% | |||||
| Deerfield Partners, L.P. | 8.4% | |||||
| James E. Flynn | 8.4% | |||||
|
Indivior PLC
13G/A
INDV · G4766E116
|
3.7% |
11/13/2025
Event 11/10/2025
|
||||
| Deerfield Mgmt, L.P. | 3.7% | |||||
| Deerfield Management Company, L.P. | 3.7% | |||||
| Deerfield Partners, L.P. | 3.7% | |||||
| James E. Flynn | 3.7% | |||||
|
Oscar Health, Inc.
13G/A
OSCR · 687793109
|
0% |
11/13/2025
Event 9/30/2025
|
||||
| Deerfield Mgmt, L.P. | 0% | |||||
| Deerfield Management Company, L.P. | 0% | |||||
| Deerfield Partners, L.P. | 0% | |||||
| James E. Flynn | 0% | |||||
|
AdaptHealth Corp.
13G/A
AHCO · 00653Q102
|
8.5% |
11/13/2025
Event 9/30/2025
|
||||
| Deerfield Mgmt, L.P. | 7.2% | |||||
| Deerfield Mgmt IV, L.P. | 4.9% | |||||
| Deerfield Partners, L.P. | 7.2% | |||||
| Deerfield Private Design Fund IV, L.P. | 4.9% | |||||
| Deerfield Management Company, L.P. | 8.5% | |||||
| James E. Flynn | 8.5% | |||||
|
Savara Inc.
13G
SVRA · 805111101
|
6.7% |
11/5/2025
Event 10/30/2025
|
||||
| Deerfield Mgmt, L.P. | 6.7% | |||||
| Deerfield Management Company, L.P. | 6.7% | |||||
| Deerfield Partners, L.P. | 6.7% | |||||
| James E. Flynn | 6.7% | |||||
|
Brookdale Senior Living Inc.
13G/A
BKD · 112463104
|
4.9% |
8/22/2025
Event 8/22/2025
|
||||
| Deerfield Mgmt, L.P. | 4.9% | |||||
| Deerfield Management Company, L.P. | 4.9% | |||||
| Deerfield Partners, L.P. | 4.9% | |||||
| James E. Flynn | 4.9% | |||||
|
BridgeBio Oncology Therapeutics, Inc.
13G
BBOT · 107924102
|
6.2% |
8/18/2025
Event 8/11/2025
|
||||
| Deerfield Mgmt, L.P. | 3.1% | |||||
| Deerfield Mgmt V, L.P. | 3.1% | |||||
| Deerfield Partners, L.P. | 3.1% | |||||
| Deerfield Private Design Fund V, L.P. | 3.1% | |||||
| Deerfield Management Company, L.P. | 6.2% | |||||
| James E. Flynn | 6.2% | |||||
|
Vera Therapeutics, Inc.
13G
VERA · 92337R101
|
5.3% |
6/11/2025
Event 6/6/2025
|
||||
| Deerfield Mgmt, L.P. | 5.3% | |||||
| Deerfield Management Company, L.P. | 5.3% | |||||
| Deerfield Partners, L.P. | 5.3% | |||||
| James E. Flynn | 5.3% | |||||
|
Owens & Minor, Inc.
13G/A
ACH · 690732102
|
0% |
5/13/2025
Event 3/31/2025
|
||||
| Deerfield Mgmt, L.P. | 0% | |||||
| Deerfield Management Company, L.P. | 0% | |||||
| Deerfield Partners, L.P. | 0% | |||||
| James E. Flynn | 0% | |||||
|
Embecta Corp.
13G/A
EMBC · 29082K105
|
4.7% |
5/13/2025
Event 3/31/2025
|
||||
| Deerfield Mgmt, L.P. | 4.7% | |||||
| Deerfield Management Company, L.P. | 4.7% | |||||
| Deerfield Partners, L.P. | 4.7% | |||||
| James E. Flynn | 4.7% | |||||
|
Mallinckrodt plc
13G/A
MNKTQ · G5890A102
|
4.1% |
5/13/2025
Event 3/31/2025
|
||||
| Deerfield Mgmt, L.P. | 4.1% | |||||
| Deerfield Mgmt IV, L.P. | 0% | |||||
| Deerfield Partners, L.P. | 4.1% | |||||
| Deerfield Private Design Fund IV, L.P. | 0% | |||||
| Deerfield Management Company, L.P. | 4.1% | |||||
| James E. Flynn | 4.1% | |||||
|
DocGo Inc.
13G/A
DCGO · 256086109
|
4.95% |
2/13/2025
Event 2/13/2025
|
||||
| Deerfield Mgmt, L.P. | 4.95% | |||||
| Deerfield Management Company, L.P. | 4.95% | |||||
| Deerfield Partners, L.P. | 4.95% | |||||
| James E. Flynn | 4.95% | |||||
|
Ventyx Biosciences, Inc.
13G/A
VTYX · 92332V107
|
0.8% |
2/13/2025
Event 12/31/2024
|
||||
| Deerfield Mgmt, L.P. | 0.8% | |||||
| Deerfield Management Company, L.P. | 0.8% | |||||
| Deerfield Partners, L.P. | 0.8% | |||||
| James E. Flynn | 0.8% | |||||
|
Prelude Therapeutics Incorporated
13G/A
PRLD · 74065P101
|
0% |
2/13/2025
Event 12/31/2024
|
||||
| Deerfield Mgmt, L.P. | 0% | |||||
| Deerfield Management Company, L.P. | 0% | |||||
| Deerfield Partners, L.P. | 0% | |||||
| James E. Flynn | 0% | |||||
|
Kura Oncology, Inc.
13G/A
KURA · 50127T109
|
0% |
2/13/2025
Event 12/31/2024
|
||||
| Deerfield Mgmt, L.P. | 0% | |||||
| Deerfield Management Company, L.P. | 0% | |||||
| Deerfield Partners, L.P. | 0% | |||||
| James E. Flynn | 0% | |||||
|
Catalyst Pharmaceuticals, Inc.
13G/A
CPRX · 14888U101
|
2.6% |
2/13/2025
Event 12/31/2024
|
||||
| Deerfield Mgmt, L.P. | 2.6% | |||||
| Deerfield Management Company, L.P. | 2.6% | |||||
| Deerfield Partners, L.P. | 2.6% | |||||
| James E. Flynn | 2.6% | |||||
|
Alignment Healthcare, Inc.
13G/A
ALHC · 01625V104
|
3.8% |
2/13/2025
Event 12/31/2024
|
||||
| Deerfield Mgmt, L.P. | 3.8% | |||||
| Deerfield Management Company, L.P. | 3.8% | |||||
| Deerfield Partners, L.P. | 3.8% | |||||
| James E. Flynn | 3.8% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.